This site is intended for Healthcare Professionals only

Keep going!  (0% complete)

quiz close icon

module menu icon High-risk medicines

Many medicines or their metabolites are eliminated from the body via the kidneys. In renal impairment, these medicines will tend to accumulate, leading to toxicity. Dialysis will replace some of the excretory functions of the kidneys, but is still not equivalent to fully functioning kidneys. It is important to amend doses of renally-excreted medicines according to the patient’s degree of renal impairment, or the type of dialysis they are undergoing. In order to do this, it is necessary to calculate the patient’s creatinine clearance (CrCl), or their estimated glomerular filtration rate (eGFR), and have knowledge of the type of renal replacement therapy the patient is receiving.

If a medicine’s metabolism and/or excretion is unaffected by renal impairment, it may be used at usual doses and the patient should be monitored for signs of increased sensitivity to the effects of the medicine.

High-risk medicines include:

  • Those with a narrow therapeutic index that are excreted via the kidneys, e.g. digoxin and aminoglycosides
  • ACEIs, ARBs, NSAIDs
  • Those that can accumulate in renal impairment and affect other systems in the body, e.g. antibiotics causing seizures
  • Those metabolised by the liver but with pharmacologically active metabolites that are excreted via the kidneys, e.g. morphine, which is metabolised in the liver to the 3- and 6-glucoronides. The metabolites are up to six times more potent than the parent medicine, and are excreted via the kidneys, which means they will accumulate in severe renal impairment leading to side effects such as respiratory depression and excessive sedation
  • Those known to be directly nephrotoxic, e.g. NSAIDs, aminoglycosides, methotrexate and other chemotherapeutic agents such as cisplatin.
  • Change privacy settings